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POLISMORFISME GENETIK DALAM ENZIM METABOLISME 
XENOBIOTIK FASA I DAN FASA II DALAM POPULASI MALAYSIA DAN 
KECENDERUNGAN KE ATAS KANSER KOLOREKTUM 
 
ABSTRAK 
 
Kanser kolorektum Sporadik adalah penyakit multi faktorial dan faktor-faktor yang 
menyumbang kepada etiopatogenesis termasuk tabiat pemakanan dan gaya hidup dan 
juga kecenderungan genetik. Pendedahan kepada persekitaran karsinogen melalui 
komponen pemakanan dan asap rokok juga dikaitkan dengan peningkatan risiko 
kanser kolorektum. Walau bagaimanapun, faktor-faktor kecenderungan genetik yang 
dikaitkan dengan insiden kanser kolorektum masih lagi tidak dapat 
ditentukan. Variasi genetik di dalam gen-gen metabolisme xenobiotic telah 
dihipotesiskan untuk bertindak balas terhadap sebatian karsinogen dan seterusnya 
memberi risiko kepada perkembangan kanser kolorektum. Oleh itu, kajian kawalan 
kes yang melibatkan 566 subjek kajian (255 pesakit kanser kolorektum sporadik dan 
311 kumpulan kawalan) telah dilaksanakan di Pusat Genom Manusia, Universiti 
Sains Malaysia dalam tempoh 2009-2011, untuk menyiasat pengaruh 
genetik polimorfisme-gen bagi beberapa metabolizing xenobiotic dalam risiko kanser 
kolorektum. Sepuluh polimorfisme dari 6 gen pengekodan enzim yang terlibat dalam 
metabolisme xenobiotic (GSTT1, GSTM1, GSTP1 Ile105Val, CYP1A2 G3860A, 
CYP1A2 T739G, CYP1A2 C729T, NAT1 C1095A, NAT2 G191A, NAT2 A803G, 
NAT2 G857A) telah dipilih sebagai calon Nukleotida Polimorfisme Tunggal untuk 
menentukan pengaruhnya terhadap analisis secara tunggal atapun gabungan genotip 
bagi risiko kanser kolorektum dan dengan tujuan utama untuk mengenal pasti 
genotip pelindung dan / atau risiko. Selepas mendapat persetujuan bertulis, darah 
periferi dari pesakit dan kumpulan kawalan diambil, DNA diekstrak dan proses 
genotip dilakukan dengan menggunakan pendekatan tindakbalas rantaian polimerase-
polimorfisme kepanjangan serpihan pembatas (PCR-RFLP) dan kaedah tindakbalas 
rantaian polimerase (PCR) secara multipleks. Genotip dikategorikan ke dalam 
homozigus normal, heterozigus mutasi dan homozigus mutasi.  Polimorfisme 
dianggarkan dengan mengira purata kebarangkalian (OR) dan mengandaikan selang 
keyakinan (CI) 95%. menggunakan regresi logistik tanpa syarat. Pada menilai risiko 
yang dikaitkan dengan genotip mutasi secara tunggal, CYP1A2 A3860A, CYP1A2 
 xviii 
 
T739G, GSTP1 Val / Val genotip dan sifar GSTT1 menunjukkan menunjukkan risiko 
yang signifikan untuk kecenderungan kanser kolorektum. Apabila dianalisis dalam 2 
kombinasi, risiko yang sangat tinggi pada kombinasi genotip CYP1A2 
A3860A/T739T, GSTT1 (-/-)/ GSTM1 (-/-), (GSTT1 (-/-)/GSTP1 Ile / Ile), (GSTT1 (-
/-)/ GSTP1 Ile / Val) diperhatikan.  Analisis gabungan bagi tiga genotip, GSTM1 (-/-
)/ GSTT1 (-/-)/ GSTP1 Ile / Ile) muncul sebagai genotip yang mempunyai 
kecenderungan risiko yang tinggi dikaitkan dengan kanser kolorektum. Dengan ini 
mencadangkan bahawa Nukleotida Polimorfisme Tunggal dikaji mungkin 
menggalakkan kecenderungan terhadap kanser kolorektum sporadik mengikut 
pengaktifan mereka terhadap bahan kimia karsinogen dan / atau penurunan 
keupayaan sel untuk menyahtoksik karsinogen tersebut.Kesimpulannya, Nukleotida 
Polimorfisme Tunggal dalam gen metabolizing xenobiotic, menunjukkan risiko 
putatif yang ketara dan penanda genetik dengan kecenderungan kanser kolorektum, 
sama ada secara tunggal atau kombinasi, boleh dianggap sebagai penanda kerentanan 
genetik 
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GENETIC POLYMORPHISMS IN THE PHASE I AND PHASE II 
XENOBIOTIC METABOLIZING ENZYMES IN MALAYSIAN 
POPULATION AND THEIR INFLUENCE ON COLORECTAL CANCER 
SUSCEPTIBILITY 
 
ABSTRACT 
 
Sporadic Colorectal Cancer (CRC) is a multifactorial disease and factors contributing 
to its etiopathogenesis include dietary and lifestyle habits on one hand and genetic 
predisposition on the other hand. Exposure to environmental carcinogens through 
dietary components and cigarette smoke are associated with an increased risk of 
CRC. However, the genetic predisposition factors associated with CRC development 
largely remain undetermined. It was hypothesized that genetic variations in 
xenobiotic metabolism genes may play a role in how individuals will respond to 
carcinogenic compounds and hence affect the risk of developing CRC. So, this case-
control study which involved 566 study subjects (255 histopathologically confirmed 
sporadic CRC patients and 311 normal healthy controls) was designed and 
undertaken at Human Genome Centre, University Sains Malaysia during the period 
2009-2011, to investigate the influence of genetic polymorphisms of few xenobiotic 
metabolizing genes in CRC susceptibility risk. Ten polymorphisms from 6 genes 
encoding enzymes involved in xenobiotic metabolism (GSTT1, GSTM1, GSTP1 
Ile105Val, CYP1A2 G3860A, CYP1A2 T739G, CYP1A2 C729T, NAT1 C1095A, 
NAT2 G191A, NAT2 A803G, NAT2 G857A) were selected as candidate SNPs to 
determine their influence, either singly or as combination genotypes, in CRC 
susceptibility risk and with the ultimate aim of identifying putatively protective 
and/or at risk genotypes. After getting informed consent, peripheral blood of all 
study subjects were collected, DNA extracted and genotyping carried out using PCR-
 xx 
 
RFLP and multiplex PCR methods. Genotypes were categorized into homozygous 
major, heterozygous variant and homozygous variant. The risk of CRC associated 
with these polymorphisms were estimated by calculating Odds Ratios (ORs) and 
95% confidence intervals using unconditional logistic regression. On evaluating the 
risk associated with the variant genotypes singly, CYP1A2 A3860A, CYP1A2 
T739G, GSTP1 val/val genotypes and GSTT1 null showed significant risk 
association with CRC predisposition. When analyzed in 2 way combinations, 
remarkably increased risk was observed for carriers of CYP1A2 A3860A/T739T, 
GSTT1 (-/-)/ GSTM1    (-/-), (GSTT1 (-/-)/ GSTP1 Ile/Ile), (GSTT1 (-/-)/ GSTP1 
Ile/Val) genotype combinations. In triple genotype combination analysis, the GSTM1 
(-/-)/GSTT1 (-/-)/ GSTP1 Ile/Ile) genotype combination emerged as high risk 
predisposition genotype associated with CRC susceptibility risk. It is reasonable to 
suggest that these SNPs studied might be promoting CRC susceptibility through their 
capability of increased activation of chemical carcinogens and/or decreased ability of 
cells to detoxify carcinogens. In conclusion, the SNPs of xenobiotic metabolizing 
genes showing significant risk association with CRC predisposition, either singly or 
in combination, may be considered as putative high risk predisposition genotypes 
and as candidate genetic markers of CRC susceptibility. 
 
 
 
 
 
CHAPTER 1 
 
INTRODUCTION 
1.1 What is Cancer? 
 
As a result of aging of populations and changes in lifestyle associated with economic 
development, cancer is becoming a more important health problem in Asian 
countries. Cancer is a general name for a group of more than 100 diseases, all 
characterized by uncontrolled cell proliferation, invasion to the surrounding tissues 
and spread to other parts of the body where they begin to grow and form  new 
tumors, a process called metastasis. When cells go out of control, they start to divide 
uncontrollably and form lumps or masses of tissue called tumors. Tumors may be 
benign or malignant. Tumors that are localized and demonstrate limited growth are 
generally considered as benign. Benign tumors are harmless growths which cannot 
invade and spread to other parts of the body and so are not life threatening. 
Malignant tumors invade and metastasize to distant sites of the body and so are 
harmful and life threatening. All cancers are malignant tumors. 
 
Normal body cells grow, divide and die in an orderly fashion, following cell 
regulatory mechanisms. Normal cells start to divide out of control as a result of 
damage to DNA (mutations). By accumulation of more and more DNA damages a 
normal cell will get transformed to tumor cell.  
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Generally, when DNA gets damaged, the cell either repairs the damage or the cell 
dies by the process known as apoptosis (programmed cell death). When the rates of 
new cell growth and old cell death are kept in balance it is considered as normal 
tissue. If the balance is disrupted it can result in uncontrolled cell growth or loss of a 
cell's ability to undergo apoptosis (cell death).  
 
Apoptosis or programmed cell death is a mechanism where the old or damaged cells 
normally undergo self destruction. However, the initial stages of malignant tumor or 
cancer may start with benign growth, and later, further accumulation of mutations 
will change it to malignant growth. Cancerous growths will occur when there is loss 
of normal growth control mechanism. Cancer occurs when a cell‟s gene mutations 
make the cell unable to correct DNA damage and unable to commit suicide.  
 
Generally, cancer is a result of mutations that inhibit oncogene and tumor suppressor 
gene function, leading to uncontrollable cell growth. Cancer also results with the 
combination of genetic and epigenetic changes in the cells and also surrounding 
stroma and blood vessels (Kotnis et al., 2005). The disruptions of several molecular 
pathways in the cell occur because of the genetic alterations.  
 
Most human cancers are derived from epithelial tissues and the loss of cell‟s 
adhesion and cell‟s polarity may also be important in early stages of cancer. Then it 
invades into adjacent tissues and form metastases, and this is observed in advanced 
tumors (Andreas and Inke, 2007). Evan and Vousden (2001) reported that most of 
the cancer mutations in genes that cause deregulated cell proliferation and suppressed 
cell death, will lead to tumor progression.  
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The etiopathogenesis of cancer is very complex and cancer can be classified into 
hereditary and non-hereditary cancer. The hereditary cancers occur due to germline 
mutations in the tumour suppressor or proto-oncogenes which are transmitted from 
one generation to another. The non-hereditary cancer or sporadic cancers arise 
sporadically through somatic mutations and are believed not to be transmitted 
through mutations from one generation to another (Kotnis et al., 2005). 
 
 The analysis of the genetic risk has shown that, most of sporadic cancers (non-
hereditary) develop in genetically predisposed individuals, and that the 
predisposition is the result of genetic variations in several low penetrance genes and 
not due to a single mutation (Imyanitov et al., 2004; Houlston and Tomlinson, 2001). 
Low penetrance genes could act as marker to predict cancer risk and may also play 
an important role in carcinogenesis.  
 
Susceptibility to sporadic cancer is reported to be caused by the interaction of genetic 
variants or single nucleotide polymorphisms (SNPs) in low penetrance genes with 
the environmental exposures. Carcinogenesis is considered as a multihit, multistep 
process which involves multiple qualitative and quantitative changes in gene 
expression, arising as a result of inherited or acquired (somatic) mutations or also as 
a consequence of infection with a tumor virus. 
 
 
 
 
 
 4 
 
1.1.1 Cancers classification into 5 groups 
 
1. Carcinomas : which are characterized by cells that cover the internal and   
external parts of the body such as lung, breast, colorectal   
cancer 
 
2. Sarcomas  : which are cancers affecting the cells located in the bone,  
cartilage, fat, connective tissue, muscle and other supportive 
tissues. 
 
3. Lymphomas : are cancers that affect the lymph nodes and immune system 
tissues. 
 
4. Leukemias  : are cancers affecting the cells in the bone marrow and often 
accumulate in the blood stream. 
 
5. Adenomas  : are cancers arising in the glandular tissues such as thyroid,  
pituitary gland, the adrenal gland etc. 
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1.1.2 Diagnosis and staging of cancer 
 
Extracting cells from the suspected or affected tissues, through aspiration, biopsy or 
surgery and observing them under the microscope after certain specific staining 
technique, is the best way to diagnose a cancer. The procedure is known as 
cytopathological or histopathological or haematopathological confirmation of a 
cancer diagnosis. 
 
 Molecular diagnostics and imaging techniques are also used to diagnose cancer. 
After a diagnosis is made, the cancers are staged according to TNM system. T (1-4) 
indicates the size and direct extent of the primary tumor. N (0-3) indicates the degree 
to which cancer has spread to nearly lymph nodes, M (0-1) indicates whether the 
cancer has metastasized to other organs of the body. For example, a small tumor that 
has not spread to lymph nodes or distant organs is staged as (T1, N0, and M0).  
 
Lower numbers indicate that the cancer has spread less. While most stage 1 tumors 
are curable, most stage 4 indicates advanced cancers which are usually inoperable 
and untreatable.  
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1.1.3 Cancer Treatment 
 
Cancer treatment generally depends on the type of cancer, the stage of the cancer, 
(how much it has spread) age, health status and additional characteristics. No single 
treatment is available for cancer and patients often receive a combination of 
therapies. Treatments usually fall into the following categories: Surgery, radiation, 
chemotherapy, hormone therapy.  
 
1.1.4 Cancer prevention 
 
Cancers that are closely linked to life style habits are the easiest to prevent. As 
examples, avoidance of tobacco and alcohol habits can significantly lower the risk of 
several types of cancer. Diet is an important part of cancer prevention since the food 
we eat has been linked to several types of cancer. Systematic screening in order to 
detect small irregularities or tumors as early as possible even if there are no clear 
symptoms is also part of cancer prevention strategies: Breast self-examination, 
mammograms, oral cavity self examination, testicular self-examination and pap 
smear tests are common screening methods for various cancers. 
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1.2 COLORECTAL CANCER 
 
Colon and rectum are parts of the digestive system. Colon also known as the large 
intestine is the last part of the digestive tract and the rectum is the very end of the 
large intestine that opens at the anus. Colorectal cancer (CRC) is cancer that starts in 
either the colon or the rectum of an individual where there is uncontrolled growth of 
the cells that line the inside of the colon or rectum. The development of the CRC is 
within the walls of their colon and/or rectum tissue through benign polyp‟s formation 
into villous adenomatous polyps.  
 
CRC develops as a result of progressive accumulation of genetic and epigenetic 
alterations that lead to a series of histopatho`logical changes, initiated by transition 
from normal mucosa to adenoma to carcinoma. So, the developement of CRC occurs 
serially and is classified into several stages based on the degree of invasion. 
 
 In 1988, Vogelstein et al. have characterized several of the molecular pathways 
occurring in progressive pathological stages, from adenoma to carcinoma and lead to 
cancer. When the cancer is confined only to the walls of the bowel, it is categorized 
as stage I and having a 90% or more curative chances with 5 year survival rates after 
resection (Vogelstein and Kinzler,1993). More advanced stage with the presence of 
distant metastases was categorized as stage IV and for this stage IV tumors, the 5 
year survival drops up to 15% (Gatta et al., 1998; Watson, 2006). Countries with 
more advanced specialiazed health care will have a better 5-year survival rate of 
chances (Boyle & Langman, 2000).  
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According to Markowitz and Bertagnolli (2009), eventhough recent advances in 
chemotherapy treatment have improved the survival of CRC, stage IV CRC is 
usually incurable.  
 
1.3 Hereditary and sporadic CRC 
 
CRC can be divided into hereditary (familial) CRC and sporadic CRC (Hemminki 
and Czene, 2002). The hereditary types, such as hereditary nonpolyposis colorectal 
cancer (HNPCC) (or also called as Lynch syndrome) and familial adenomatous 
polyposis (FAP) show an autosomal dominant  mode of inheritance, early age of 
disease onset and multiple members in a certain family affected with same type of 
CRC.  
 
Hereditary types of CRC have been reported to have an association with tumors 
located in the proximal portion of the colon. Earlier studies have observed stronger 
associations of family history of CRC with proximal versus distal tumors (Burt et al., 
1985; Lynch et al., 1993). Few other studies also strongly favoured that having a 
family history of colorectal increased the risk of developing cancer of the rectum 
(Newcomb et al., 1999; Johns & Houlston, 2001).  
 
According to studies reported, it is estimated that HNPCC accounts approximately 
5% and inherited adenomatous polyposis coli cancer (APC) mutations accounts for 
less than 0.5% (Jass, 2000; Samowitz et al., 2001). Among those individuals having 
family history of colorectal cancer among first-degree relatives, about 12–15% were 
diagnosed with HNPCC (Potter et al., 1993; Slattery & Kerber, 1994). The 
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hereditary component increases the risk still higher, resulting in CRC being 
diagnosed at a younger age (<45 years). Several susceptibility genes responsible for 
HNPCC have been identified. Inherited mutations in a group of DNA mismatch 
repair genes (MMR genes) MLH1, MSH2, MSH6 PMS2 genes are believed to be 
responsible for HNPCC and inherited mutations of Adenomatous Polyposis Coli 
(APC) gene is responsible for FAP (Kloor et al., 2004; Sun et al., 2005; Sheng et al., 
2010). Slattery et al. (2000) reported that having a family history of colorectal cancer 
significantly increased the risk of having colon cancer compared to rectal cancer. 
 
Sporadic CRC is the most common type of CRC. Sporadic CRC accounts 75%-85% 
of CRC and occurs in the absence of a family history or in the presence of family 
history not fulfilling criteria for one of the inherited syndromes. Sporadic mutations 
arising in somatic cells of the body may result in any type of cancer, depending on 
the where the mutation occurs and these mutations will not be passed on to the next 
generation. Genetic variations in the form of low to moderate penetrance allele 
interacting with environmental factors may predispose individuals to sporadic CRC. 
When the low penetrance genes have altered function due to SNPs, this may affect 
the gene-environment and gene-gene interaction and increase the risk of sporadic 
cancers.  
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1.4 Prevalence of CRC 
 
Colorectal cancer (CRC) is the second most common cause of cancer deaths in 
developed and developing countries including Malaysia (Malaysian Cancer 
Statistics, 2006). CRC is a major cause for mortality among men and women 
worldwide with an incidence of more than 500,000 deaths and approximately 1 
million cases per year.  CRC is the third most common cancer in men (663,000 
cases, 10% of the total) and the second in women (570,000 cases, 9.4% of the total) 
worldwide. Eventhough 60% of the cases occur in developed countries, the incidence 
is increasing in devoloping countries also, including Malaysia. Incidence rates are 
substantially higher in men than women (overall sex ratio of ASR 1:4:1) (Ferlay et 
al., 2010). 
 
In Netherlands, colorectal cancer is the second cause of deaths from malignant 
diseases in women (after breast cancer) and the third cause of deaths in men (after 
lung and prostate cancer) (de Jong et al., 2002). In France, it is the third most 
frequent cancer (>36,000 new cases were diagnosed in 2000) and the second cause of 
cancer-related deaths (16,000 deaths were caused by CRC in 2000 for both sexes) 
(Küry et al., 2007). 
 
 The highest CRC incidence rates reported among males were in Europe, North 
America and Oceania as well as in Asia where in the highest rates were recorded in 
Japan and Singapore. This is most likely due to differences in environmental 
exposures or life style factors (Botteri et al., 2008).  
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Among the 3 Asian countries, Japan showed the highest incidence of CRC among 
males. It is believed to be because of the modifications in dietary intake as they had 
increased intake of the western food which also contribute to increased obesity rate 
in Japan (Kuriki & Tajima, 2006; Matsushita et al., 2008). 
 
In Asian countries, females were also shown to have higher CRC incidence, however 
lower than the males. The lower rates may be related to the lifestyle habits which are 
associated with CRC, such as smoking and alcohol intake and also the obesity status 
that differ among men and women (Mackay & Amos, 2003; Frezza et al., 2006).  
 
According to Malaysian Cancer registry, CRC ranks second most common cancer in 
women and has surpassed lung cancer to become the most common cancer in men 
(Yip et al., 2010). The incidence of CRC diagnosed among Malaysians in Peninsular 
Malaysia, was a total of 21,464 cases consisting 9,400 males and 12,064 females. 
Colon cancer was reported to be predominant among men aged 50 years and above 
(National Cancer Registry, 2003). Among all CRC cancer cases reported in 
Malaysia, 16.2% were males and 10.6% were females (Yip et al., 2010). 
 
There are many different ethnic groups in Malaysia of which the three 3 predominant 
groups are Malay, Chinese and Indian. Differences in incidence of colorectal cancer 
have been reported among these 3 ethnic groups. Yip et al. (2010) reported that 
Chinese have a significantly higher incidence of colon and rectal cancers with Age 
Standardized Rate (ASR) of 21.4 per 100,000 compared to Malaysian Indians (11.3 
per 100,000) and Malay groups (9.5 per 100,000) (Malaysian Cancer Statistics, 
2006). These observations on ethnic differences suggest that genetic factors have an 
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important etiological role in colorectal cancer susceptibility (National Cancer 
Registry, 2003). 
 
Even though the incidence of CRC is higher among Asians, CRC mortality has 
decreased in some of the Asian and Eastern European countries. Hyodo et al. (2010) 
reported that the incidence and mortality of CRC has been increasing rapidly in the 
Asian countries except Japan and Singapore. This decreasing rate in CRC mortality 
has been attributed to the improvement in the CRC treatment or early detection by 
screening or other symptom recognition (Chia et al., 2001; Ribes et al., 2009).   
 
1.5 Risk factors of CRC 
 
Sporadic CRC is a multifactor caused disease, i.e., there are many factors 
contributing to its development. These include the dietary and lifestyle habits on one 
hand and genetic predisposition on the other hand (de Jong et al., 2002). The natural 
history and role of several risk factors in the aetiology of CRC are becoming more 
clearly understood and the genetic events involved in CRC susceptibility are being 
uncovered with increasing frequency.  
 
Alcohol consumption and tobacco smoking have been reported to increase CRC risk, 
whereas the regular intake of non-steroidal anti-inflammatory drugs reduces risk. 
Tobacco smoke contains toxic and cancer causing chemicals such as nitrosamines 
that are harmful to both smokers and nonsmokers.  
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Cigarette smoke contains a variety of carcinogenic compounds, including polycyclic 
aromatic hydrocarbons, nitrosamines, and aromatic amines (Manabe and Wada, 
1991) and has shown an increased risk of lung, bladder, gastric, kidney, and 
pancreatic cancer.  
 
Studies have shown an increased risk of colorectal cancer among men and women 
with moderate alcohol intake in America, Europe and Japanese populations (Cho et 
al., 2004; Mizoue et al., 2008). An association between alcohol consumption and 
colorectal cancer risk among drinkers and non-drinkers has been established. 
 
 Besides tobacco and alcohol consumption, obesity and lack of physical activity may 
act as risk factors for colorectal cancer. According to Gunter and Leitzmann (2006), 
obese individuals have altered metabolic status that modify the colorectal mucosa 
which becomes more vulnerable to carcinogenesis and thus lead to colorectal cancer. 
 
Another risk factor which influences CRC risk is lack of physical activity which is a 
critical component of energy balance. Physical activity most likely influences the 
development of colon cancer in multiple ways. Physical activity may protect against 
colon cancer and tumor development through its role in energy balance, hormone 
metabolism, insulin regulation and by decreasing the time the colon is exposed to 
potential carcinogens. Physical activity has also been found to alter a number of 
inflammatory and immune factors, some of which may influence colorectal risk 
(Meyerhardt et al., 2006). 
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Epidemiologic studies on Western populations have emphasized the large 
contribution of food and lifestyle to sporadic CRC risk. Consumption of high-fat and 
low-fiber diets, as well as alcohol, tobacco and red or processed meat, overcooked 
and charred food etc have been shown to expose humans to high levels of polycyclic 
aromatic hydrocarbons and aromatic amines which are carcinogens (Küry et al., 
2007).  
 
World Cancer Research Fund and the American Institute for Cancer Research 
reported that consumption of high fruit and vegetable diet could reduce the chances 
of having cancers (Kearney et al., 1996). Cruciferous vegetables (cauliflower, 
cabbage, broccoli and several green vegetables) have been shown to possess 
chemopreventive activity against a variety of other cancers such as lung and prostate 
cancer through their effects on the metabolism of pro-carcinogens (Verhoeven et al., 
1996; Cohen et al., 2000).  
 
Earlier, the incidence of colorectal cancer in Japanese was low relative to the US 
population. However, as the Japanese diet has become more similar to the western 
diet, the incidence of colorectal cancer had increased (Katoh et al., 1996). In 
Malaysia, because of the rapid move towards westernized diet and changes in life 
style habits, people are increasingly being exposed to carcinogens, also resulting in 
an increase in number of colorectal cancer cases (Lim et al., 2003).  
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Acrylamide has been found in certain foods, with especially high levels in potato 
chips, french fries and other food products produced by high temperature cooking 
(above 120°C). Food and cigarette smoking are major sources of exposure to 
acrylamide. Laboratory animal studies have demonstrated acrylamide to be a 
mutagen and probable carcinogen. Heterocyclic amines (HCAs) and polycyclic 
aromatic hydrocarbons (PAHs) are chemicals formed when muscle meat, including 
beef, pork, fish and chicken is cooked using high temperature methods, such as pan 
frying or grilling directly over an open flame.  
 
The formation of HCAs and PAHs is influenced by the type of meat, the cooking 
time, the cooking temperature and the cooking method. Meat cooked at high 
temperatures, especially above 120°C or that are cooked for a long time tend to form 
more HCAs. Grilled or barbecued chicken and steak all have high concentrations of 
HCAs. Cooking methods that expose meat to smoke or charring contribute to PAH 
formation (Jãgerstad and Skog, 2005).  
 
Sugimura et al. (1977) has reported the production of mutagens by heating meat and 
fish. Methanol extracts from charred parts of grilled sun-dried, beefsteak and 
hamburger were found to contain mutagens. Studies have clarified that the mutagenic 
activity is mainly derived from heterocyclic amine (HCA) compounds, which are 
produced during cooking from the meat constituent‟s creatinine, amino acids and 
sugars. Over-intake of calories, fat and salt may act to enhance carcinogenesis, 
through various pathways, while more fiber in the diet can suppress colon 
carcinogenesis.  
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1.6 Genetic predisposition to CRC  
 
Current knowledge of colorectal carcinogenesis indicates a multifactorial and multi-
step process that involves various genetic alterations and several disease pathways. 
An important research element unraveling these carcinogenic pathways to CRC is to 
gain an understanding of genetic susceptibility to CRC at the population level.  
 
Genetic susceptibility (essentially synonymous with predisposition) is a broad term 
because not only does it describe genetic mutations that convey high levels of 
predisposition affecting a small proportion of the population like DNA mismatch 
repair (MMR) gene mutations for HNPCC susceptibility (Lynch Syndrome), but it 
also includes a large number of unidentified genetic variations that are much more 
common in the population, but convey lower level of risk and often involve 
interaction with specific exposure in the environment. Single nucleotide 
polymorphisms (SNPs) are central to this research.  
 
Environmentally sensitive genetic polymorphisms are some of the most recently 
described cancer predisposing factors. Genetic predisposition due to polymorphisms 
and mutations in low penetrance genes has been increasingly realized to play an 
important role in determining the outcome of carcinogen exposure and the risk of 
cancer development. Susceptibility to sporadic colorectal cancer are due to several 
combinations of allelic variants in low-penetrance genes. Eventhough the low-
penetrance alleles may contribute to the effect on the risk of colorectal cancer, the 
combination with other susceptibility alleles as well as environmental risk factors can 
result in an inrease in colorectal cancer risk. The genes grouped as low penetrance 
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genes play important role in cariconogenesis and have been suggested as markers for 
predicting the cancer risk. Altered function of low penetrance genes due to SNPs 
may affect the gene environment and gene-gene interaction and thereby could 
increase the risk of developement of sporadic cancers. 
 
1.7 The present study – Importance 
 
Genetic predisposition involves low penetrance genes or gene variants. Genetic 
predisposition explains why all individuals exposed to the same type and dose of 
carcinogen do not develop cancer. Development of sporadic CRC is not only due to 
exogenous or endogenous carcinogens, but also due to their interactions with genes 
that are involved in the detoxification of these carcinogens, repair of DNA damage 
and control of cell signaling and cell cycle. 
 
In order to protect against the effects of carcinogens present in the diet as well as in 
the environment, the body has a host of metabolic enzymes (including activating and 
detoxifying enzymes) that play an important role in the metabolism of endogenous 
and exogenous chemicals such as polycyclic aromatic hydrocarbon (PAHs), 
Aromatic Amines (AAs) and Heterocycic Amines (HAs). All of these compounds 
(PAHs, AAs and HAs) are known to be metabolized by a variety of Phase I and 
Phase II xenobiotic metabolizing enzymes including Glutathione S-transferase, 
Cytochorome P450s and N-acetyltransferases.  
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HCAs and PAHs become capable of damaging DNA only after they are metabolized 
by specific enzymes in the body by a process called “bioactivation”. Studies have 
shown that the activity of these enzymes can differ among people based on their 
genetic constitution (Sinha et al., 1995; Moonen et al., 2005; Butler et al., 2005). 
 
Genetic polymorphisms in low penetrance genes may account for why some people 
are more sensitive than others to environmental carcinogens or cancer promoters 
associated with CRC. Exposure to environmental carcinogens such as aromatic 
amines found in over cooked or preserved meat and cigarette smoke are associated 
with an increased risk for CRC. Examination of broad spectrum of SNPs along 
multiple disease pathways should help to understand CRC predisposition or 
susceptibility risk. Genetic polymorphisms  of  genes encoding enzymes  involved in 
Xenobiotic metabolic pathways  and genes encoding enzymes  involved in DNA 
damage repair have been studied as candidate genes from different parts of the 
world.   
 
1.8 Xenobiotic Metabolizing Enzymes and CRC susceptibility risk 
 
The xenobiotic metabolizing enzymes are divided on the basis of their metabolism 
into phase I and phase II enzymes (Kotnis et al., 2005). The phase I and phase II 
enzymes are important candidates because of their ability to metabolize the 
environmental carcinogens and hence in the susceptibility of sporadic CRC 
(McIlwain et al., 2006).  
 
 19 
 
The enzymes belonging to the Cytochrome P450 superfamily (CYPs) are grouped 
under phase I and those belonging to Glutathione S Transferase family (GSTs) and 
N-acetyltranferases (NATs) are grouped under phase II (Kotnis et al., 2005). CYP 
enzymes comprise of 70–80% of all phase I XMEs (Evans & Relling, 1999) and are 
categorized in a systematic nomenclature for the CYP gene superfamily in all 
eukaryotes and prokaryotes. Most CYP1 family members are very hydrophobic and 
these are substrates for the CYP1 enzymes (CYP1A1, CYP1A2 and CYP1B1) (Nebert 
et al., 2004). More than 20 variants (SNP) of the CYP1A2 gene have been identified. 
Some of the SNPs are found in CYP1A2 upstream sequence and intron 1 region and 
it is believed that these SNPs will affect the CYP1A2 enzymes activity (Ghotbi et al., 
2007).  
 
Human Glutathione S Transferases (GSTs) are composed of three main families: 
cytosolic, mitochondrial and microsomal (or membranebound). Most of these GSTs 
polymorphisms are Single Nucleotide Polymorphisms (SNPs) and less frequently as 
deletion. The products of GSTM1, GSTT1, and GSTP1 genes are detoxification 
enzymes which are able to metabolize a wide range of different chemicals (Beckett 
and Hayes, 1993). Deletion polymorphisms of these GSTM1 and GSTT1 genes have 
previously been shown with different frequencies in various populations (Garte et al., 
2001). Null genotype for GSTT1 and GSTM1 causes an absence of the enzymes 
activity, or may decrease the ability to eliminate carcinogens and may therefore be at 
increased cancer risk, including colorectal cancer.  
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N-acetyltransferases 1 and 2 (NAT1 and NAT2) are two other phase II enzymes 
which are polymorphically expressed in a variety of tissues including colorectal 
tissues (Ilett et al., 1994: Hickman et al., 1998). NAT1 and NAT2 catalyze N- and O-
acetylation of several xenobiotics including potential carcinogens that leads to 
detoxification or activation of the substrate (Hein et al., 1993). The phenotypes of 
NAT2 gene are varying in populations of different ethnic or geographic origin. 
Allelic variants of the NAT2 gene are determined by a pattern of SNPs resulting in 
slow (SA), Intermediate (IA) and rapid acetylators (RA). This causes individual 
differences in the NAT2 metabolic capacity.  
 
Many of the polymorphic genes of the metabolism of xenobiotics show considerable 
ethnic differences in respect to allelic distribution (e.g. rare alleles, gene 
amplifications and pseudogenes). From Asia pacific region, most of the reports on 
genetic risk modification were from Japan, and several studies among various 
European populations had also estimated allele frequencies and risk genotypes. 
Remarkable variations in the metabolic phenotypes and genotypes have been 
reported for different ethnic and/or geographic populations (Sung et al., 2005). 
 
There is a large volume of   literature  available  where genetic polymorphisms in  
genes encoding xenobiotic metabolizing  enzymes such as CYP 1A family. 
Glutathione S transferases, N –Acetyl transferases etc have been documented as 
important genetic factors in the development of CRC. Several studies have reported 
an association of lung cancer (Kumar et al.,  2009), bladder cancer (Grando & 
Kuasne, 2009)  as well as colorectal cancer (Sachse et al., 2002; Yeh et al., 2005) 
with polymorphisms in major SNPs of CYP1A2, CYP1A2 and GSTM1 genotypes and 
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GSTT1 and GSTP1  combination genotypes.  However, the results have been 
inconsistent and contradictory. 
 
Moreover, there is paucity of information on the nature of  predisposing  genotype (s)  
that contribute  susceptibility to CRC  in Malaysian  patients as no such  previous 
studies have been undertaken in Malaysia . There are two factors that in combination 
make the search for CRC predisposition genes very important. First, identification 
and removal of colorectal adenomas (precancerous lesion) almost certainly greatly 
reduce CRC incidence.  
 
Identification of CRC, before they present clinically may have similar benefits. 
Regular, frequent and effective screening for CRC is not currently available at the 
population level. This warrants the need for identification of genetic risk factors that 
contribute to CRC susceptibility (predisposition). A major part of this challenge is to 
choose the ideal pathways related to CRC susceptibility and select the candidate 
genes and examine their associated risk for CRC susceptibility.  
 
Genetic factors such as SNPs have been widely studied as factors influencing the risk 
of CRC. Identification of  the contributory role of SNPs in low penetrance genes 
involved in xenobiotic metabolism as genetic susceptibility factors in sporadic CRC 
is important as it is associated with lifestyles such as diet, tobacco and alcohol.  
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Genetic polymorphisms in several candidate genes  involved in xenobiotic 
metabolism may influence individual variation in susceptibility that may be 
associated with risk of developing sporadic colorectal cancer. It was hypothesized 
that genetic variations in these xenobiotic metabolism genes may play a role in 
how individuals will respond to carcinogenic compounds and hence affecting the 
risk of developing CRC.  
 
It was hoped that an evaluation of interaction between multiple genes including 
Phase I (eg : Cytochorme P450s family) and Phase II XMEs (GSTs and NATs 
family) may give a better understanding on genetic susceptibility in colorectal 
cancer. So, these three multiple gene superfamilies (Cytochrome P450s, Glutatione 
S-Transferases, N-acetyltransferase genes) were selected because of their important 
role in the activation and/or detoxification of xenobiotics and environmental 
chemicals.  
 
A case-control study was designed to investigate the role of SNPs of genes encoding 
enzymes involved in Phase 1 and Phase II xenobiotic metabolism in mediating CRC 
predisposition in Malaysian population.  
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1.9 Objective (s) of the Research:   
        This study was designed to understand  the  fundamental role of  environmental 
sensitive genetic polymorphisms  of genes encoding Phase I and Phase II  xenobiotic 
metabolizing enzymes , either singly and/or in various combinations, as predisposing 
factors  in the etiopathogenesis of spoaradic colorectal cancer in Malaysia. 
Specific Objectives 
1. To genotype the Malaysian Colorectal Cancer patients and normal healthy 
controls for polymorphisms in genes encoding xenobiotic metabolizing enzymes 
such as CYP1A2, GSTM1, GSTT1, GSTP1, NAT1 and NAT2. 
 
2. To investigate the genotype frequencies of polymorphisms of these genes in 
Malaysian Colorectal Cancer patients and normal controls. 
 
3. To determine the association risk of variant genotypes of these genes singly 
and/or in combinations with sporadic CRC susceptibility. 
 
4. To identify the fundamental „at high risk‟ genotype associated with sporadic 
Colorectal Cancer susceptibility.  
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CHAPTER 2 
 
LITERATURE REVIEW 
 
2.1 Xenobiotic Metabolizing Enzymes 
 
It is well documented that sporadic cancers arise as a result of interaction between 
external exposure and genetic susceptibility caused by low penetrance genes. One 
type of such susceptibility is related to the metabolism of carcinogens. Tobacco 
smoking, diet and infections/inflammation are some of the major factors for cancer 
causation in humans (Doll and Peto, 1981). Studies in humans appear to strongly 
suggest the possibility that many of the sporadic cancers are initiated by 
chemical/dietary exposures which damage the DNA in cells. Then it will proceed 
through several stages including additional genetic alterations that can transform the 
normal cells to fully malignant cells (Vogelstein et al., 1988) 
 
Even though so many individuals are exposed to environmental carcinogens on a 
routine basis, only a fraction of carcinogen exposed individuals develop cancer. 
Humans differ in their susceptibility to diseases including cancer. Besides 
environmental exposures, gender and ethnicity, genetic background of an individual 
could also play a significant role in determining his/her susceptibility risk for a 
particular type of cancer.  
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Etiologically sporadic CRC is a complex and multifactorial disease that is linked to 
both exogenic and endogenous factors. Accumulating evidence indicates that 
susceptibility to sporadic cancers, including CRC, is mediated by both genetic and 
environmental factors.  
 
Genotoxic substances in the diet are related to sporadic CRC development. 
Endogenous genotoxic agents such as reactive oxygen species are produced in line 
with the calorific intake. Overintake of calories, macrocomponents such as fatty 
acids and salts may act to enhance colorectal carcinogenesis through various 
pathways, while more fibre in the diet can suppress colon carcinogenesis. In this 
regard, genetically determined differences in the effectiveness of activation and/or 
detoxification of potential carcinogens from environmental exposures diet etc might 
be importantly involved in CRC susceptibility. Interindividual differences in cancer 
susceptibility may be mediated in part through polymorphic variability in the genes 
encoding enzymes involved in xenobiotic metabolism, including bioactivation and 
detoxification of carcinogens. 
 
Xenobiotic metabolism is the set of metabolic pathways that modify the chemical 
structure of xenobiotics, which are compounds such as carcinogens, drugs, poisons 
and etc which are foreign to an organism‟s normal biochemistry. Candidate genes 
encoding Xenobiotic Metabolizing Enzymes (XMEs) may result in increased or 
decreased carcinogen activation (Nebert et al., 1996; Gonzalez, 1995). XMEs are 
group of proteins which are responsible for the metabolism most the xenobiotic 
compounds such as drugs, endogenous compounds and also environment pollutants. 
XMEs will undergo biotrasformation process, when enzyme chemically modifying 
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the drugs and other xenobiotics to increase their water solubility to facilitate their 
elimination from the body.  
 
2.2 Phase I Xenobiotic Metabolizing Enzymes 
 
Three multiple gene superfamilies (Cytochrome P450s, N-acetyltrasferase and 
Glutathione S-Transferase genes ) are polymorphically expressed genes and may be 
positively (or inversely) associated with susceptibility to cancer because of their 
important role in the detoxification (or activation) of xenobiotic and environmental 
chemicals. As far as CRC is concerned, enzymes involved in xenobiotic metabolic 
pathways are of interest because of their possible role in detoxification of chemical 
compounds and carcinogens in the diet might be modulated by genetic 
polymorphisms in biotransformation genes. The xenobiotic metabolism genes or 
biotransformation genes are generally divided into phase I enzymes (most of which 
represent cytochrome P450s) and Phase II enzymes (Glutathione S-Transferase and 
N-acetyltransferase). 
 
Phase I detoxification involves a group of enzymes, referred to as Cytochrome P450 
family. Almost 50-100 enzymes make up the cytochrome P450 systems, with each 
enzyme working more efficiently at neutralizing certain classes of chemicals. The 
activity of the various cytochrome P450 enzymes varies significantly from one 
individual to another, based on genetics, the individual‟s level of exposure to 
chemical toxins and his or her nutritional status. Since the activity of Cytochrome 
P450 varies so much, so does an individual‟s risk for various diseases. 
